Pacira BioSciences (PCRX) Cost of Revenue (2010 - 2026)

Pacira BioSciences' Cost of Revenue history runs 17 years deep, the most recent figure standing at $36.4 million for Q1 2026.

• On a quarterly basis, Cost of Revenue rose 6.14% year-over-year to $36.4 million in Q1 2026; TTM through Mar 2026 was $151.9 million, a 3.47% decrease from a year earlier, with the FY2025 full-year figure at $149.7 million, down 12.13% from the prior year.
• Cost of Revenue slipped to $36.4 million in Q1 2026 per PCRX's latest filing, from $40.3 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $61.9 million in Q4 2022 and bottomed at $34.3 million in Q3 2025.
• The 5-year median for Cost of Revenue is $40.9 million (2025), against an average of $43.6 million.
• Across the five-year window, Cost of Revenue surged 58.73% in 2022 and declined 27.65% in 2025, its largest moves.
• Year by year, Cost of Revenue stood at $61.9 million in 2022, then slipped by 22.97% to $47.7 million in 2023, then fell by 16.37% to $39.9 million in 2024, then climbed by 1.04% to $40.3 million in 2025, then declined by 9.64% to $36.4 million in 2026.
• Per Business Quant, the three latest PCRX Cost of Revenue figures stand at $36.4 million (Q1 2026), $40.3 million (Q4 2025), and $34.3 million (Q3 2025).